Attached files
file | filename |
---|---|
8-K - LIVE FILING - BIOLASE, INC | htm_55500.htm |
BIOLASE ANNOUNCES RECORD DATE FOR PREVIOUSLY
ANNOUNCED PROPOSED RIGHTS OFFERING
IRVINE, Calif., October 30, 2017 BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that its Board of Directors has set the record date of 5:00 p.m., Eastern Time on November 8, 2017, for its previously announced proposed rights offering to holders of shares of its common stock. The remaining terms of the rights offering, including the subscription price, will be set prior to November 8, 2017.
A Registration Statement relating to these securities has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement is declared effective. When it becomes available, a copy of the final prospectus forming a part of the Registration Statement may be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering, Georgeson LLC, toll free at (800) 561-3991. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser
systems in dentistry and medicine and also markets, sells, and distributes dental imaging
equipment, including digital x-rays and CAD/CAM scanners. BIOLASEs products are focused on
technologies that advance the practice of dentistry to both dentists and their patients. BIOLASEs
proprietary laser products incorporate approximately 210 patented and 90 patent-pending
technologies designed to provide biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge technology at competitive
prices to deliver the best results for dentists and patients. BIOLASEs principal products are
revolutionary dental laser systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE
has sold approximately 34,900 laser systems to date in over 90 countries around the world. Laser
products under development address BIOLASEs core dental market and other adjacent medical and
consumer markets.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASEs estimated or anticipated future
results or other non-historical facts are forward-looking statements, as are any statements in this
press release concerning prospects related to BIOLASEs strategic initiatives and anticipated
financial performance. Forward-looking statements can also be identified through the use of words
such as anticipates, expects, intends, plans, believes, seeks, estimates, may,
will, and variations of these words or similar expressions. Readers are cautioned not to place
undue reliance on these forward-looking statements, which reflect BIOLASEs current expectations
regarding existing trends, and its strategic initiatives, and speak only as of the date of this
release. Actual results may differ materially from BIOLASEs current expectations depending upon a
number of factors affecting BIOLASEs business. These factors include, among others, adverse
changes in general economic and market conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of customer acceptance of new product
offerings and market changes, risks associated with managing the growth of the business, and those
other risks and uncertainties that may be detailed, from time-to-time, in BIOLASEs reports filed
with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking
statements contained herein.
For Further Information Contact:
|
||
BIOLASE, Inc. Harold C Flynn. Jr |
Georgeson LLC (800) 561-3991 |
|
President and Chief Executive Officer
|
1290 Avenue of the Americas, 9th Floor | |
hflynn@biolase.com
|
New York, NY 10104 | |
888-424-6527
|